APP
CLVS

Avantax Planning Partners’s Clovis Oncology, Inc. CLVS Stock Holding History

Avantax Planning Partners’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-136
Closed -$4K – 1293
2018
Q3 		$4K Buy
+136
New +$5.26K ﹤0.01% 1210
2018
Q2 		– Sell
-136
Closed -$7K – 1614
2018
Q1 		$7K Buy
+136
New +$7.93K ﹤0.01% 1230

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Avantax Planning Partners's CLVS Position: Q4 2018 in Review

Avantax Planning Partners sold out of Clovis Oncology, Inc. (CLVS) in Q4 2018, closing a stake of 136 shares — an estimated $4K sold.

Avantax Planning Partners first reported a position in CLVS in Q1 2018 and held it in 2 quarters. The position peaked at $7K in Q1 2018. 165 funds tracked by Wall St. Rank hold CLVS as of Q4 2018.

  • Avantax Planning Partners reported no remaining Clovis Oncology, Inc. position as of Q4 2018 after selling out during the quarter.
  • Avantax Planning Partners sold 136 Clovis Oncology, Inc. shares in Q4 2018, an estimated $4K.
  • Avantax Planning Partners first reported a position in Clovis Oncology, Inc. in Q1 2018 and held it in 2 quarters.
  • Avantax Planning Partners's Clovis Oncology, Inc. position peaked at $7K in Q1 2018.
  • 165 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2018.

Based on Avantax Planning Partners's 13F filing for Q4 2018, filed 14 Feb 2019.